Healthcare Equipment and Supplies
Company Overview of Fenwal Inc.
Fenwal Inc., a blood technology company, develops products for transfusion medicine and cell therapies. It offers component collection systems, separators, and plasmapheresis systems for donor centers and mobile drives; manual collection products and systems to address blood component collection and filtration needs, which comprise automated blood component separators, whole blood collection systems, and blood-pack units; and mononuclear cell collection, therapeutic plasma exchange, and cellular therapy products, as well as specialty products for therapeutics. The company also provides specialty products, such as segment sampling devices, tubing sealers, sterile tube connection systems, hemo...
Three Corporate Drive
Lake Zurich, IL 60047
Founded in 1949
Key Executives for Fenwal Inc.
Chief Financial Officer and Senior Vice President
Chief Executive Officer of Fresenius Kabi Region North America and President of Fresenius Kabi Region North America
President of Medical Devices for Fresenius Kabi North America
Chief Technology Officer and Senior Vice President
Chief Information Officer and Senior Vice President
Compensation as of Fiscal Year 2015.
Fenwal Inc. Key Developments
Fenwal Receives FDA Clearance to Include New Clinical Data in the Product Label of its Platelet Additive Solution, InterSol
Mar 24 14
Fenwal announced it has received FDA clearance to include new clinical data in the product label of its platelet additive solution, InterSol(TM) (PAS 3). A multi-center, non-randomized, open-label retrospective medical chart review study involving about 14,000 transfusions looked at adverse events related to platelet transfusion with and without additive solution. Platelet transfusions using Fenwal InterSol led to a 0.55% adverse event reaction rate, while transfusions using only plasma platelets led to a 1.37% adverse event reaction rate. Clinical experience has suggested that allergic transfusion reactions may be reduced by replacing a portion of the total plasma volume with platelet additive solution. Fenwal InterSol solution replaces approximately 65% of the plasma used for platelet storage, on platelets collected on the Fenwal Amicus(R) separator. The results of this study are consistent with these previous findings. No adverse safety trends were identified after a review of all the adverse events by the Independent Clinical Events Committee. Platelet transfusions using Fenwal InterSol resulted in a 0.29% allergic reaction rate, while transfusions using only plasma platelets resulted in a 0.82% allergic reaction rate. Febrile Non-Hemolytic Transfusions reaction events were associated with 0.17% of platelet transfusions with Fenwal's InterSol and 0.50% of transfusions with plasma platelets.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries